261 related articles for article (PubMed ID: 10556185)
1. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease.
Ware RE; Zimmerman SA; Schultz WH
Blood; 1999 Nov; 94(9):3022-6. PubMed ID: 10556185
[TBL] [Abstract][Full Text] [Related]
2. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
[TBL] [Abstract][Full Text] [Related]
3. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
[TBL] [Abstract][Full Text] [Related]
4. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
Ware RE; Zimmerman SA; Sylvestre PB; Mortier NA; Davis JS; Treem WR; Schultz WH
J Pediatr; 2004 Sep; 145(3):346-52. PubMed ID: 15343189
[TBL] [Abstract][Full Text] [Related]
5. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
Greenway A; Ware RE; Thornburg CD
Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
[TBL] [Abstract][Full Text] [Related]
6. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Ware RE; Helms RW;
Blood; 2012 Apr; 119(17):3925-32. PubMed ID: 22318199
[TBL] [Abstract][Full Text] [Related]
7. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
8. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Wang WC; Dwan K
Cochrane Database Syst Rev; 2013 Nov; (11):CD003146. PubMed ID: 24226646
[TBL] [Abstract][Full Text] [Related]
9. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
[TBL] [Abstract][Full Text] [Related]
10. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
[TBL] [Abstract][Full Text] [Related]
12. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.
Ware RE; Schultz WH; Yovetich N; Mortier NA; Alvarez O; Hilliard L; Iyer RV; Miller ST; Rogers ZR; Scott JP; Waclawiw M; Helms RW
Pediatr Blood Cancer; 2011 Dec; 57(6):1011-7. PubMed ID: 21826782
[TBL] [Abstract][Full Text] [Related]
13. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience.
Jain DL; Apte M; Colah R; Sarathi V; Desai S; Gokhale A; Bhandarwar A; Jain HL; Ghosh K
Indian Pediatr; 2013 Oct; 50(10):929-33. PubMed ID: 23798623
[TBL] [Abstract][Full Text] [Related]
15. Use of hydroxyurea in prevention of stroke in children with sickle cell disease.
Lefèvre N; Dufour D; Gulbis B; Lê PQ; Heijmans C; Ferster A
Blood; 2008 Jan; 111(2):963-4; author reply 964. PubMed ID: 18182580
[No Abstract] [Full Text] [Related]
16. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
17. Sickle cell disease and stroke.
Verduzco LA; Nathan DG
Blood; 2009 Dec; 114(25):5117-25. PubMed ID: 19797523
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.
Zimmerman SA; Schultz WH; Burgett S; Mortier NA; Ware RE
Blood; 2007 Aug; 110(3):1043-7. PubMed ID: 17429008
[TBL] [Abstract][Full Text] [Related]
20. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
